« Caught in in FDA's Web | Main | Follow-on, Oh Canada »

March 25, 2008

Failed Drugs or Failed Pathways?

by Peter Pitts

Interesting article in the Wall Street Journal on the use of genetic tools to resuscitate failed compounds.

Here how the story begins:

“As pharmaceutical makers find it increasingly difficult to bring new drugs to market, they are turning to genetic tools to seek uses for medicines that failed to make it out of the development pipeline.

The discovery of new links between genes and diseases can help not only to design new treatments, but to salvage drugs that are shelved when they come up short in clinical trials.”

And here’s the rest of the story:

http://online.wsj.com/article/SB120631682077958247.html?mod=dist_smartbrief

The better understanding of genetic tools (via a robust collaboration of industry, academia, and government) will both expedite failure (which lowers the cost of R&D) and provide a broader spectrum for success (which rewards it).

Sound familiar? Correct – the Critical Path.

Posted by peterpitts at March 25, 2008 09:01 AM

Trackback Pings

TrackBack URL for this entry:
/cgi-bin/mt-tb.cgi/187

Comments

Post a comment

Name:

Email Address:

URL:
Remember Me? YesNo

Comments: (you may use HTML tags for style)

To protect against spam, off-topic and abusive comments, all comments are reviewed before being posted to the blog. Please limit your comments to two on each topic and don't use all caps. Also, please note that some comments related to specific ownership issues are forwarded to customer assistance rather than posted here.